Domov › Melanóm › Massachusetts
Klinické štúdie Melanóm v štáte Massachusetts
29 štúdií pre Melanóm hľadá účastníkov v zariadeniach v štáte Massachusetts.
Mestá v štáte Massachusetts
Oficiálny text štúdie (anglicky)
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07751042BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Baystate Medical Center, Springfield
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05136196Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06047379A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07492680DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- Massachusetts General Hospital Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT07288112Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT04899908A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07070232Cryoablation+Ipilimumab+Nivolumab in Melanoma
- Massachusetts General Hospital Cancer Center, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT05779423Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
12 Months – 30 Years · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- a 1 ďalších
Prebieha náborObservačná štúdia
Do veku 25 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT02402244Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 8. 2026 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 8. 2026 · NCT05592626A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 7. 2026 · NCT06150664A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
Prebieha náborFáza 1/2
6 Months – 17 Years · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT02332668Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 19 až 110 · Všetky pohlavia · Aktualizované 29. 6. 2026 · NCT02012699Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 5. 2026 · NCT05225428Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 5. 2026 · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 5. 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Massachusetts General Hospital, Boston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 5. 2026 · NCT07015190A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- Dana Farber, Boston
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 4. 2026 · NCT06624644A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Massachusetts General Hospital, Boston
Prebieha náborFáza 2/3
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 2. 4. 2026 · NCT06581406Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 2. 2026 · NCT05549297ACTengine® IMA203 Combined With mRNA-4203
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 1. 2026 · NCT06946225Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 až 100 · Všetky pohlavia · Aktualizované 5. 1. 2026 · NCT05428007SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 28. 10. 2025 · NCT03452774A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 10. 2025 · NCT04370587A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 2. 2025 · NCT05669430Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 11. 2024 · NCT04787042Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 3. 2024 · NCT05280314Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.